Stifel Nicolaus analyst James Condulis has maintained their bullish stance on NAMS stock, giving a Buy rating on November 5.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
James Condulis has given his Buy rating due to a combination of factors that highlight the promising outlook for NewAmsterdam Pharma Company. The recent data from the American Heart Association (AHA) conference has provided a favorable environment for the lipid space, particularly for non-statin treatments, which are gaining traction in the market. This trend is expected to benefit NewAmsterdam’s obicetrapib, as it is well-positioned to capture a significant market opportunity following the anticipated success of the PREVAIL trial.
Furthermore, the competitive landscape is advantageous for obicetrapib, as it demonstrates strong efficacy in lowering LDL-C and Lp(a) levels, with a unique profile that includes benefits for small particles and diabetes. The absence of major adverse cardiovascular events (MACE) data from competitors like Merck may further validate obicetrapib’s differentiated profile. Additionally, the broader cardio-metabolic mergers and acquisitions activity is likely to provide further momentum for the company’s growth. Overall, these factors contribute to a positive outlook for NewAmsterdam Pharma’s stock, justifying the Buy rating.
In another report released on November 5, RBC Capital also maintained a Buy rating on the stock with a $44.00 price target.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NAMS in relation to earlier this year.